Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
M Sarzotti-Kelsoe, RT Bailer, E Turk, C Lin… - Journal of …, 2014 - Elsevier
The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of
reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a …
reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a …
Common features of enveloped viruses and implications for immunogen design for next-generation vaccines
FA Rey, SM Lok - Cell, 2018 - cell.com
Enveloped viruses enter cells by inducing fusion of viral and cellular membranes, a process
catalyzed by a specialized membrane-fusion protein expressed on their surface. This review …
catalyzed by a specialized membrane-fusion protein expressed on their surface. This review …
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska… - … England Journal of …, 2021 - Mass Medical Soc
Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1
A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …
neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune …
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine
SM Hammer, ME Sobieszczyk, H Janes… - … England Journal of …, 2013 - Mass Medical Soc
Background A safe and effective vaccine for the prevention of human immunodeficiency
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime …
virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime …
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
X Wu, ZY Yang, Y Li, CM Hogerkorp, WR Schief… - Science, 2010 - science.org
Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1–infected
individuals, but the virologic basis of their neutralization remains poorly understood. We …
individuals, but the virologic basis of their neutralization remains poorly understood. We …